The World Health Organization says Ebola transmission is declining in some of the hardest-hit areas of the Democratic Republic of the Congo. The improvement is most visible in parts of Ituri province, the main center of the outbreak. However, the epidemic continues to expand in other areas. Official data through Sept. 13 showed 7,258 confirmed cases and 3,510 deaths across seven provinces, with the national case fatality ratio at 48.4%.

NEW YORK / RankWire.AI / – New York City health officials detected Legionella DNA in a Yankee Stadium cooling tower during an investigation into a South Bronx outbreak. The city had confirmed 11 Legionnaires’ disease cases by Tuesday night. One person died, while three patients remained hospitalized. The New York City Health Department found preliminary positive PCR results in 10 of 24 cooling towers sampled across ZIP codes 10451 and 10456.

The World Health Organization has urged a wider Ebola response in the Democratic Republic of the Congo as transmission continues across several provinces. Congo had recorded 6,250 confirmed cases and 3,039 deaths by Sept. 1, according to the latest government figures. The outbreak has affected 60 health zones in six provinces. Authorities have also recorded 1,439 recoveries, while the case fatality rate stands at 48.6%.

Health Minister Roger Kamba confirmed that the government initiated the immunization campaign utilizing doses of the Ervebo vaccine to safeguard frontline personnel operating across impacted eastern provinces.

The European Commission has expanded its Ebola response with a €2.1 million purchase of PCR tests for the Bundibugyo virus outbreak. The agreement covers open-platform tests that laboratories can use with existing systems. Shipments are due to start in August as health teams confront a large outbreak centered in the Democratic Republic of the Congo and affecting parts of the wider region.

Triple-negative breast cancer accounts for 10% to 15% of Australia’s approximately 21,000 annual breast cancer diagnoses but causes a disproportionate number of deaths. This subtype lacks estrogen, progesterone, and HER2 receptors, rendering conventional targeted hormone therapies ineffective. Lead investigators demonstrated that when miR-342 levels fall, a cancer-driving pathway called E2F becomes overactive, allowing dormant cancer cells to spread throughout the body and form dangerous secondary tumors.